10:41 AM EDT, 10/21/2024 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) said Monday the US Food and Drug Administration has approved a new drug application for Pyridostigmine Bromide extended-release tablets.

The tablets will be used by the US Army and its allies as pretreatment against the effects of soman nerve agent poisoning, the pharmaceutical company said.

The once-daily tablets offer an alternative to a current Pyridostigmine Bromide product that needs to be administered three times a day, Amneal said.

Price: 8.61, Change: +0.03, Percent Change: +0.35